Solopharm is a Russian pharmaceutical company producing medicines, medical devices and dietary supplements.

Solopharm

Company history

July 2011

Start of the plant construction and laying of the foundation

March 2013

Completion of the construction and a start of an office work

June 2014

Launch of the 1st stage. The first series of infusion solutions are released

July 2015

Launch of the 2nd stage. Production of ophthalmic and nasal products in multidose form

April 2017

Launch of the 3rd stage - 10 new lines. The GMP certificate is received

April 2019

Solopharm becomes the fastest growing company for the second year in a row. «Platinum Ounce», the prestigious pharmaceutical award is received

May 2019

ISO 13485:2016 certificate for the export of medical devices is received

July 2020

Launch of the biotechnological developments’ laboratory

September 2020

Foundation for solid dosage forms plant is laid.
Solopharm is included in TOP-20 of pharmaceutical companies according to Forbes magazine

February 2021

Solopharm is in Top-10 of the most rapidly developing companies in retail segment by the end of 2020

July 2021

Solopharm receives the EAEU GMP Certificate

September 2021

Solopharm is ranked #16 on the Forbes’ 2021 list of best domestic drug manufacturers

January 2022

Solopharm launches a new manufacturing site for dietary supplements

April 2022

The plant for production of solid dosage forms is opened

June 2022

Confirmation of the Solopharm medical device quality management system to the ISO 13485: 2016 requirements

October 2022

Solopharm entered the TOP-10 in the «Made in St. Petersburg and Leningrad region» nomination, «Fontanka.ru - Recognition and Influence» award

December 2022

Solopharm is ranked #1 in terms of online sales growth rate (according to AlphaRM for 11M-2022)

April 2023

Launch of the 4th stage of the liquid dosage forms production. Increasing the manufacturing facilities of existing and new drugs production, incl. new release forms

April 2023

Launch of the 2nd stage of the dietary supplements plant. Production of dietary supplements in capsules

May 2023

Launch of the plant for design, production, and installation of clean rooms

June 2023

Groundbreaking of the plant for the production of biotechnological products

October 2023

Solopharm entered again the TOP-10 in the «Made in St. Petersburg and Leningrad region» and «Employer of the year» nominations, «Fontanka.ru - Recognition and Influence» awards

March 2024

Launch of the ESS pharmaceutical warehouse

November 2024

Solopharm entered the TOP-10 finalists of the Award «Fontanka.ru: Recognition and Influence» in the nomination «Made in St. Petersburg and Leningrad Region»

March 2025

Solopharm is ranked №8 in the Forbes ranking of the «20 best pharmaceutical manufacturers in Russia – 2025»

April 2025

Launch of the 2nd microbiological laboratory at E11 for quality control of solid dosage forms, soft dosage forms and dietary supplements plants

8th place in Forbes 2025: Top 20 Pharmaceutical Manufacturers in Russia (Forbes, March 2025)

Oleg Zherebtsov, CEO of Solopharm, ranked 2nd in “Influence Rating for 2024: Entrepreneurs, Heads of Commercial Structures” (PharmVestnik, Feb. 2025)

No. 1 in ophthalmologist recommendations for the company's products (Ipsos Prindex, Q1 2024)

No. 1 in recommendations of the company's products among ENT doctors (Ipsos Prindex, Q1 2024)

No. 5 for company product recommendations among pediatricians (Ipsos Prindex, Q1 2024)

Solopharm #1 among all manufacturers in Ophthalmology in 2024 (based on data from IQVIA Retail Audit, IQVIA Contracts 44FZ, Headway Ophthalmic Surgery, by volume)

Solopharm in the Top 5 manufacturers by sales growth rate in volume terms in the retail ECOM segment in 2024 (DSM estimates, Feb. 2025)

Solopharm unveiled a new milestone – the Matrix Wall, its proprietary cleanroom design and manufacturing facility

Solopharm in Top 5 manufacturers by number of physician prescriptions (IPSOS, Jan. 2025, PrIndex)

Solopharm ranked in the Top 15 manufacturers with the highest share of launches in prescription portfolios in 2024 (Ipsos, Feb. 2025)

Solopharm ranked 9th in “Influence Rating for 2024: Local Manufacturing Companies” (PharmVestnik, Feb. 2025)

Solopharm in 4th place in the ranking of state segment manufacturers in 2024 (DSM, in volume terms, Feb. 2025)

Solopharm ranked No. 1 by volume of ampoule solution sales in the retail market in 2024 (DSM, pharmacy sales, Feb. 2025)

Solopharm in the Top 10 manufacturers in digital promotion in 2024 (Ipsos, Feb. 2025)

Solopharm in the Top 20 drug manufacturers by pharmacy sales value in 2024 (DSM, Mar. 2025; based on IQVIA data, Feb. 2025)

Solopharm in Top 10 drug manufacturers by volume of sales in 2024 (DSM, whole pharmaceutical market, Mar. 2025)

Solopharm in the Top 3 manufacturers of INN Sodium Chloride in government procurement at the end of 2024 (DSM, pharmacy sales, Mar. 2025)

Solopharm ranked 6th among companies with the highest number of OTC launches in 2024 (DSM, Mar. 2025)

Solopharm in Top 20 drug manufacturers by value of pharmacy sales in 2m 2025 (based on CRPT data, Apr. 2025)

Fridifin in the Top 10 successful product launches in Q4 2024 (IPSOS, Feb. 2025)

Trecrezan in the Top 15 OTC brands in pharmacy sales in 2024 (DSM, Mar. 2025)

Angidak recognized as one of the successful brands with high growth in “Knowledge” and “Consumption” indicators (IPSOS, Mar. 2025)

Photo 8th place in Forbes 2025: Top 20 Pharmaceutical Manufacturers in Russia (Forbes, March 2025)

More than 260 drugs in the Solopharm portfolio in various therapeutic areas

Photo 8th place in Forbes 2025: Top 20 Pharmaceutical Manufacturers in Russia (Forbes, March 2025)

Global presence

Карта мира
Belarus
Azerbaijan
Armenia
Vietnam
Georgia
Kyrgyzstan
Tajikistan
Kazakhstan
Cambodia
Uzbekistan
Morocco
Mongolia
Qatar
Kuwait

Solopharm today

Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is